Stocks of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) traded higher last session on Wall Street, down -3.01% to $1.29.
According to the data, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) has 6 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $1.30, we find $2.00. Given the previous closing price of $1.33, this indicates a potential upside of 50.38 percent. RIGL stock price is now -9.07% away from the 50-day moving average and -0.37% away from the 200-day moving average. The market capitalization of the company currently stands at $213.96M.
A total of 4 analysts have issued a hold rating and 2 have given it a buy rating. Brokers who have rated the stock have averaged $4.18 as their price target over the next twelve months.
In other news, RODRIGUEZ RAUL R, CEO, President sold 20,340 shares of the company’s stock on Feb 06. The stock was sold for $35,595 at an average price of $1.75. Upon completion of the transaction, the CEO, President now directly owns 1,680,713 shares in the company, valued at $2.17 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 02, EVP & CMO Dummer Wolfgang sold 5,389 shares of the business’s stock. A total of $8,946 was realized by selling the stock at an average price of $1.66. This leaves the insider owning 72,459 shares of the company worth $93472.11. Insiders disposed of 36,506 shares of company stock worth roughly $47092.74 over the past 1 year. A total of 1.44% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RIGL stock. A new stake in Rigel Pharmaceuticals Inc. shares was purchased by SOLEUS CAPITAL MANAGEMENT, L.P. during the first quarter worth $16,516,000. QUBE RESEARCH & TECHNOLOGIES LTD invested $611,000 in shares of RIGL during the first quarter. In the first quarter, PUTNAM INVESTMENTS LLC acquired a new stake in Rigel Pharmaceuticals Inc. valued at approximately $340,000. MARSHALL WACE, LLP acquired a new stake in RIGL for approximately $223,000. VERITION FUND MANAGEMENT LLC purchased a new stake in RIGL valued at around $160,000 in the second quarter.
Wednesday’s opening bell rang with an opening price of $1.3500 for Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). During the past 12 months, Rigel Pharmaceuticals Inc. has had a low of $0.67 and a high of $2.04. The fifty day moving average price for RIGL is $1.4128 and a two-hundred day moving average price translates $1.2972 for the stock.
The net profit margin was -34.50% and return on equity was 291.00% for RIGL. The company reported revenue of $26.89 million for the quarter, compared to $29.82 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -9.84 percent.
